Search

This significantly revised fourth edition provides a practically orientated guide to interactions associated with antiseizure medications. It describes pharmacokinetic and pharmacodynamic antiseizure medication (ASM) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be co-prescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug interactions between ASMs; Drug interactions between ASMs and non- ASM Drugs: Interactions affecting ASMs; Drug interactions between ASMs and non ASM Drugs: Interactions affected by ASMs. The latest data on all drug interactions is presented. New agents discussed include cannabidiol, cenobamate, everolimus and fenfluramine,. Antiseizure Medication Interactions: A Clinical Guide, 4th Edition concisely presents the most recent developments and data available on the topic. Therefore, enabling physicians and allied health professionals to make more rational choices when ASM polytherapy regimens are required. It will be of interest to medical professionals in disciplines including neurology, psychiatry and pediatrics.

The 4th edition of Drug Interactions in Infectious Diseases is being split into two separate volumes – “Mechanisms and Models of Drug Interactions” and “Antimicrobial Drug Interactions”. This volume, “Mechanisms and Models of Drug Interactions,” delivers a text that enhances clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infection, and inflammation. The book provides a comprehensive review of basic clinical pharmacology with a focus on metabolism and transporter-mediated drug interactions. The chapters address materials that cannot be retrieved easily in the medical literature, including materials focused on the complex interrelationship of acute infection, inflammation, and the risk of drug interactions in the Drug-Cytokine chapter. The Food-Drug and Herb-Drug interactions chapters remain definitive resources. A new chapter on in vitro modeling of drug interactions isincluded along with updates on design and data analysis of clinical drug interaction studies. Authoritative discussion of models for regulatory decision-making on drug-drug interactions provides the necessary framework to aid antimicrobial drug development. This concise review of the mechanisms and models of drug interactions provides important insights to health care practitioners as well as scientists in drug development.

This updated third edition of a successful book is a description of both pharmacokinetic and pharmacodynamic antiepileptic drug (AED) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be coprescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between AEDs and also between AEDs and non-AEDs are described in three sections: Drug interactions between AEDs; Drug interactions between AEDs and non-AED Drugs: Interactions affecting AEDs; Drug interactions between AEDs and non-AED Drugs: Interactions affected by AEDs.Antiepileptic Drug Interactions: A Clinical Guide, 3rd Edition with its clear, concise and unambiguous content will allow physicians and allied health professionals to make more rational choices when AED polytherapy regimens are indicated. There is always a choice and avoiding highly interacting drugs and choosing drug combinations that are minimally interacting or do not interact should be the goal in treating patients with epilepsy. This book provides all the necessary information so as to allow this goal to be achieved and, if necessary, to aid effective management of AED interactions.

This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories andwith reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together,or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology.Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions,isfrequently updated. However, with information presented on a host of different platforms, and in differentformats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.

Sets the foundation for safer, more effective drug therapies With this book as their guide, readers will discover how to apply our current understanding of the pharmacogenomics of drug transporters to advance their own drug discovery and development efforts. In particular, the book explains how new findings in the field now enable researchers to more accurately predict drug interactions and adverse drug reactions. Moreover, it sets the foundation for the development of drug therapies that are tailored to an individual patient's genetics. Pharmacogenomics of Human Drug Transporters serves as a comprehensive guide to how transporters regulate the absorption, distribution, and elimination of drugs in the body as well as how an individual's genome affects those processes. The book's eighteen chapters have been authored by a team of leading pioneers in the field. Based on their own laboratory and clinical experience as well as a thorough review of the literature, these authors explore all facets of drug transporter pharmacogenomics, including: Individual drug transporters and transporter families and their clinical significance Principles of altered drug transport in drug–drug interactions, pharmacotherapy, and personalized medicine Emerging new technologies for rapid detection of genetic polymorphisms Clinical aspects of genetic polymorphisms in major drug transporter genes Future research directions of drug transporter pharmacogenomics and the prospect of individualized medicine Pharmacogenomics of Human Drug Transporters opens the door to new drug discovery and development breakthroughs leading to safer and more effective customized drug therapies.The book is recommended for pharmaceutical scientists, biochemists, pharmacologists, clinicians, and genetics and genomics researchers.

Antiepileptic Drug Interactions: A Clinical Guide, Second Edition provides a pocket-sized, systematic description of the most clinically relevant drug interactions that occur between AEDs and also between AEDs and non-AEDs. AEDs are presented alphabetically and by drug class in three sections for easy access: Drug interactions between AEDs; Drug interactions between AEDs and non-AEDs: Interactions affecting AEDs; and Drug interactions between AEDs and non-AEDs: Interactions affected by AEDs. Antiepileptic Drug Interactions: A Clinical Guide, Second Edition should help physicians make more rational choices when polytherapy regimens are indicated and should be of interest to all who treat patients with epilepsy: neurologists and neurosurgeons, trainees at all levels, general practitioners and epilepsy nurse specialists.

The revised and up-to-date third edition of Drug Interactions in Infectious Diseases delivers a text that will enhance your clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infection, and inflammation. The third edition features five new chapters that cover material not addressed in previous editions. These new chapters describe interactions with a number of drug classes such as non-HIV antiviral, antimalarial, antiparasitic, antihelmintic, macrolide, azalide and ketolide agents. A novel chapter on probe cocktail studies has been included to highlight an important research tool for drug development. These chapters address material that cannot be retrieved easily in the medical literature. The highly acclaimed food-drug interactions as well as the study design and analysis chapters remain definitive references. The newly written drug-cytokine interaction highlights the need for our improved understanding of the complex interrelationship of acute infection, inflammation, and the risk of drug interactions. Informative tables on specific drug-drug interactions are provided throughout the chapters as a quick clinical resource. The Third Edition of Drug Interactions in Infectious Diseases is a distillation of relevant drug interactions associated with antimicrobials, infection, and inflammation. This concise review of the mechanisms and strategies to manage drug interactions should be valuable to all health care practitioners. Features • Definitive reference source of up-to-date information on antimicrobial drug interactions • Informative tables on the degree of interaction for specific antimicrobial agents • In-depth discussion of mechanisms and potential mechanistic pathways of interaction • New chapters on non-HIV antiviral, antimalarial, antiparasitic, and macrolide, azalide and ketolide agents • New chapter on probe-cocktail studies as a research tool to study drug-drug interactions • Inclusionof new antimicrobial agents and their associated drug interactions • First rate chapters on study design and analysis, and drug-food interactions • A fresh perspective on drug-cytokine interactions • Authoritative chapter on regulatory considerations of drug interactions during drug development

Stockley's Drug Interactions, edited by Karen Baxter, remains the world's most comprehensive and authoritative reference book on drug interactions.: Contains detailed yet concise monographs; Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, pesticides and drugs of abuse; Based on published sources and fully referenced; Global coverage - inclusion of drugs used worldwide; Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance and gives clear guidance on how to.

Drug interactions have become a significant iatrogenic complication, with as many as 5% of hospitalizations and 7,000 deaths annually attributable to drug-drug interactions in the United States. There are several reasons these numbers have increased. First, many new medications have been brought to market in recent years. Second, advances in medical care have resulted in increased longevity and more elderly patients than ever before -- patients who are more likely to be following polypharmacy regimens. Population patterns in the U.S. have amplified this trend, with aging baby boomers swelling the patient pool and demanding treatment with medications advertised on television and in print. Fortunately, drug interactions can be prevented with access to current, comprehensive, reliable information, and the Clinical Manual of Drug Interaction Principles for Medical Practice provides just that in a user-friendly format psychiatry clinicians (including residents and nurses) and forensics experts will find indispensable. With this new edition, the book has evolved from'Concise Guide'to'Clinical Manual'and offers the expanded coverage and features healthcare providers need to keep up with this critical field. The book is well organized, with major sections on metabolism; cytochrome P450 enzymes; drug interactions by medical specialty; and practical matters, such as the medicolegal implications of drug-drug interactions and how to retrieve and review the literature. In the section on P450 enzymes, each chapter addresses what the individual enzyme does and where, its polymorphisms, and drugs that inhibit or induce activity. Each chapter also includes extensive references and study cases to help the reader understand and contextualize the information. A number of additional features enhance the book's scope and utility: • The book boasts the very latest information in the area of drug metabolism, transport, and interaction.• The chapter on P-glycoprotein (a drug transporter) was expanded from the last edition to include a broader array of transport mechanisms.• The highest ethical standard was adhered to in the development of this volume, which was not supported in any way by pharmaceutical makers or distributors. All eight contributors to this excellent resource are experts in the fields they have addressed, and clinicians can trust that the information contained in the Manual reflects the very latest research. This exceptionally practical manual is essential to maintaining the highest standard of care.

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. The unwarranted effects of medications used in psychiatry can adversely affect a treatment plan. This book is critical in helping psychiatrists and mental health professionals assess the adverse effects of drugs such as antidepressants, mood stabilizers, hypnosedatives, and antipsychotic drugs.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of psychiatric mediations. - Surpasses the Physician's Desk Reference © by including clinical case studies and independent expert analysis - Complete index of drug names - Most complete cross referencing of drug-drug interactions available - Extensive references to primary and secondary literature - Also includes information on adverse effects in pregnancy The book is divided into six sections: - Antidepressants – A general introduction to their adverse effects, followed by monographs on individual drugs and groups of drugs (including lithium) - Neuroleptic drugs – A general introduction to their adverse effects, followed by monographs on individual drugs - Hypnosedatives - A general introduction to their adverse effects, followed by monographs on individual drugs - Drugs of abuse - Drugs used to treat Alzheimer's disease - Psychological and psychiatric adverse effects of non-psychoactive drugs

This book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin (5-HT)-dopamine (DA) interactions. Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviors. Moreover, recent evidence suggests that the dysfunction of the DA and 5-HT neurotransmitter systems contribute to various mental disorders including depression, schizophrenia, drug addiction and Parkinson's disease. This extremely important topic is of wide interest within the scientific community, with relevance not only to specialists but also to general practitioners and students. The book provides a valuable contribution to the debate on new pharmacological approaches for several psychopathological states, with contributions from expert neuroscientists and pharmacologists who comprehensively survey the most significant currently active areas of dopamine/serotonin interactions. - Provides an understanding of the interaction between Serotonin and Dopamine - Appeals equally to specialists, general practitioners, students and researchers - Contributes to the debate on new pharmacological approaches to several psychopathological states - Gives a comprehensive anatomical description plus the physiology and pharmacology of dopaminergic and serotonergic systems - Singles out neuropsychiatric and suggests new therapeutic approaches

This user-friendly resource offers complete and comprehensive coverage of the difficult challenges posed by drug-drug interactions. Over 170 case vignettes illustrate a variety of interactions (DDIs) to provide an unintimidating -- even entertaining -- approach to understanding these issues. Drug-Drug Interaction Primer builds on the author's earlier work, Drug Interactions Casebook: The Cytochrome P450 System and Beyond, and features updated references throughout and 29 new cases that provide such clinical examples as: a patient diagnosed with schizoaffective disorder transitions from haloperidol to aripiprazole with disastrous results; an AIDS patient's trimethoprim-sulfamethoxazole is replaced with warfarin following atrial fibrillation, resulting in ischemic stroke; and a delusional patient on risperidone is placed on phenytoin following seizures, and delusions return. Previous cases have been revised to enhance clarity.An introduction to core concepts, which includes brief reviews of each enzyme system, brings the reader up to speed on how to think about DDIs and begin to grapple with what might seem like an imposing subject. The vignettes that follow each include a case presentation and an explanation of the mechanism by which the interaction(s) occurred, and each derives from sound clinical evidence -- not merely extrapolations from drug characteristics -- to offer a more realistic understanding of DDIs. Most of the interactions described involve the cytochrome P450 enzyme system; others involve alterations in phase II metabolism and P-glycoprotein functioning, as well as plasma protein displacement effects. The appendices detail most drug-drug interactions between psychotropic agents and contain metabolic pathways and inhibitory and inductive profiles for antidepressants, antipsychotics, and mood stabilizing agents -- as well as tables that detail all known and clinically significant DDIs between pairings of any two agents from these drug classes. An extensive index allows quick reference. Among the book's other features: • Reorganization by medical subspecialty -- psychiatry, internal medicine, neurology, surgery/anesthesia, and gynecology, oncology, and dermatology -- better facilitates clinical application.• Comprehensive tables detail substrates, inhibitors, and inducers for P450, phase II, and P-glycoprotein. • DDIs involving select nonpsychotropic agents such as tobacco, ethinylestradiol, and statins.• Exploration of the paradigm of plasma protein binding mediated DDIs in detail, with cases conveniently indexed. These cases bring DDIs alive in a way that drier descriptions cannot, and this volume introduces more original material than will be found in other sources. Drug-Drug Interaction Primer is brimming with material that can be put to immediate use, offering insights that will improve any practitioner's skills.

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and experimental data. The book consists of five sections covering the general concepts and advantages of combination therapies, the principles of drug interactions, the mechanisms of interactions, drug interactions in specific populations or in patients with co-morbid health conditions, and concludes with a look at the future directions for this field of research. The book will be of interest to all who prescribe antiepileptics to epileptic and non-epileptic patients, including epileptologists, neurologists, neuro-pediatricians, psychiatrists and general practitioners.

A concise compilation of the known interactions of the most commonly prescribed drugs, as well as their interaction with nonprescription compounds. The agents covered include CNS drugs, cardiovascular drugs, antibiotics, and NSAIDs. For each class of drugs the authors review the pharmacology, pharmacodynamics, pharmacokinetics, chemistry, metabolism, epidemiological occurrences, adverse reactions, and significant interactions. Environmental and social pharmacological issues are also addressed in chapters on food and alcohol drug interactions, nicotine and tobacco, and anabolic doping agents. Comprehensive and easy-to-use, Handbook of Drug Interactions: A Clinical and Forensic Guide provides physicians with all the information needed to avoid prescribing drugs with undesirable interactions, and toxicologists with all the data necessary to interpret possible interactions between drugs found simultaneously in patient samples.